Sökning: "Targeted adjuvant"
Visar resultat 11 - 15 av 31 avhandlingar innehållade orden Targeted adjuvant.
11. The leukocyte complexity and mutational landscape of periampullary adenocarcinoma. Morphology matters
Sammanfattning : Background: Periampullary adenocarcinomas are a heterogenous group of tumours with poor prognosis that hasnot improved considerably the last decades. Tumour morphology, i.e. intestinal type (I-type) or pancreatobiliarytype (PB-type), has been demonstrated to be a more relevant prognostic factor than anatomical origin. LÄS MER
12. New Diagnostic and Therapeutic Approaches in Adrenocortical Cancer
Sammanfattning : Adrenocortical cancer (ACC) is a rare disease that is often difficult to diagnose, and therefore often presents at an advanced stage. Various cytotoxic treatments have been tried with little success. Evaluation of new diagnostic methods and improvement of medical therapies are therefore crucial. LÄS MER
13. Rational and combinatorial protein engineering for vaccine delivery and drug targeting
Sammanfattning : This thesis describes recombinant proteins that have been generated by rational and combinatorial protein engineering strategies for use in subunit vaccine delivery and tumor targeting.In a first series of studies, recombinant methods for incorporating immunogens into an adjuvant formulation, e.g. LÄS MER
14. Mass Spectrometry-Based Protein Biomarker Discovery in Pancreatic Cancer
Sammanfattning : Background: Pancreatic cancer has the lowest survival rate among all the major cancer types. Although recent decades have seen advances in diagnostic imaging, surgical techniques, perioperative care and oncological treatment, this has not been translated into major improvements in clinical outcome. LÄS MER
15. Chemosensitivity in Breast Cancer
Sammanfattning : Breast cancer mortality in Sweden is now in decline, thanks to early detection and the wide use of adjuvant endocrine therapy and chemotherapy. While hormone receptor status is predictive of response to endocrine treatment, there is no clinically useful predictive marker of a patient’s response to chemotherapy. LÄS MER